These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32651832)

  • 1. The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
    Lodise TP; Tillotson GS; Spargo A; Bozkaya D; Massey J
    Clin Drug Investig; 2020 Oct; 40(10):961-971. PubMed ID: 32651832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
    Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia.
    Bassetti M; Melchio M; Giacobbe DR
    Expert Rev Anti Infect Ther; 2022 May; 20(5):649-656. PubMed ID: 34913817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delafloxacin: A Review in Community-Acquired Pneumonia.
    Lee A; Lamb YN; Shirley M
    Drugs; 2022 Jun; 82(8):913-923. PubMed ID: 35708893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin.
    Sharma R; Sandrock CE; Meehan J; Theriault N
    Clin Drug Investig; 2020 Oct; 40(10):947-960. PubMed ID: 32889706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP).
    Horcajada JP; Salata RA; Álvarez-Sala R; Nitu FM; Lawrence L; Quintas M; Cheng CY; Cammarata S;
    Open Forum Infect Dis; 2020 Jan; 7(1):ofz514. PubMed ID: 31988972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
    LoVecchio F; Schranz J; Alexander E; Mariano D; Meads A; Sandrock C; Moran GJ; Giordano PA
    J Emerg Med; 2021 Jun; 60(6):781-792. PubMed ID: 33731270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.
    Lodise TP; Mistry R; Young K; LaPensee K
    Clin Drug Investig; 2021 Mar; 41(3):269-275. PubMed ID: 33604769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective.
    LaPensee K; Mistry R; Lodise T
    Am Health Drug Benefits; 2019 Feb; 12(1-Supplement 1):S1-S12. PubMed ID: 30996766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delafloxacin as a treatment option for community-acquired pneumonia infection.
    Nascimento-Carvalho CM
    Expert Opin Pharmacother; 2021 Oct; 22(15):1975-1982. PubMed ID: 34346823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia.
    Gómez-Zorrilla S; Sendra E; Horcajada JP
    Expert Rev Clin Pharmacol; 2022 Jun; 15(6):671-688. PubMed ID: 35838033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
    Thabit AK; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
    van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
    BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
    Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
    Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
    J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia.
    Covington PS; Davenport JM; Andrae DA; Stryjewski ME; Turner LL; McIntyre G; Almenoff J
    J Antimicrob Chemother; 2013 Nov; 68(11):2691-3. PubMed ID: 23749951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.